Abstract
The abuse potentials of various narcotic medications were assessed by surveying 130 hospital patients who admitted to having abused prescription narcotics within the preceding six months. 85% of the subjects surveyed reported having tried controlled-release narcotic preparations for abuse purposes and 60% reported that they were of little or no use. To obtain another index of abuse potential, the author asked the subjects to estimate the street prices of various medications. The street prices of controlled-release formulations were lower than those of other narcotic medications and those of some uncontrolled nonnarcotic medications. These results suggest that controlled-release narcotic formulations may have a lower potential for abuse than do other narcotic medications. In situations where there is concern about potential abuse or diversion of prescribed narcotics, controlled-release preparations may be an appropriate alternative to high-peaking, rapid-onset opioid formulations.
This is a preview of subscription content, log in via an institution to check access.
References
Sigler KA, Guernsey BG, Ingrim NB, Buesing AA. Effect of triplicate prescription law on prescribing of schedule II drugs. Am J Hosp Pharm. 1985;42:857–9.
Weintraub M, Singh S, Byrne L, Maharaj K, Guttmacher L. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA. 1991;266:2392–7.
Zullich SG, Grasela TH, Fiedler-Kelly JB, Gengo FM. Impact of triplicate prescription program on psychotropic prescribing patterns in long-term care facilities. Ann Pharmacother. 1992;26:539–46.
Cooper JR, Czechowicz DJ, Peterson RC, Molinari SP. Prescription drug diversion control and medical practice. JAMA. 1992;268:1306–10.
Glass RM. Benzodiazepine prescription regulation: autonomy and outcome. JAMA. 1991;266:2431–3.
Stimmel B. Pain, Analgesia and Addiction: The Pharmacologic Treatment of Pain. New York: Raven Press, 1983.
Khojasteh A, Evans W, Reynolds RD. Controlled-release oral morphine sulfate in the treatment of cancer pain with pharmacokinetic correlation. J Clin Oncol. 1987;5:956–61.
Jasinski DR. Assessment of the abuse potentiality of morphinelike drugs. In: Martin WR (ed). Handbook of Experimental Pharmacology. Heidelberg, Germany: Springer Verlag, 1977.
Roberts J. In Focus. Emerg Med News. 1992;6:3–5.
Crews JC, Denson DD. Recovery of morphine from a controlled-release preparation. Cancer. 1990;66:2642–4.
National Institute on Drug Abuse. Data from the Drug Abuse Warning System, 1977. NIDA Statistical Series; 1988. U.S. Department of Health and Human Services publication ADM 88-1854.
National Household Survey on Drug Abuse: Population Estimates 1990. Rockville, MD: National Institute on Drug Abuse, 1991. U.S. Department of Health and Human Services publication ADM 91-1732.
Melzack R. The tragedy of needless pain. Sci Am. 1990;162:19–25.
Selbst SM, Clark M. Analgesic use in the emergency department. Ann Emerg Med. 1990;19:1010–3.
Marks RM, Sachar EJ. Undertreatment of medical inpatients with narcotic analgesics. Ann Intern Med. 1973;78:173–81.
Agency for Health Care Policy and Research. Acute Pain Management: Operative or Medical Procedures and Trauma. U.S. Department of Health and Human Services, 1992. AHCPR 92-0032.
American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. Skokie, IL: American Pain Society, 1992.
Brookoff D, Polomano R. Treating sickle cell pain like cancer pain. Ann Intern Med. 1992;116:364–8.
Author information
Authors and Affiliations
Additional information
Received from the University of Tennessee College of Medicine, Memphis, Tennessee.
Rights and permissions
About this article
Cite this article
Brookoff, D. Abuse potential of various opioid medications. J Gen Intern Med 8, 688–690 (1993). https://doi.org/10.1007/BF02598290
Issue Date:
DOI: https://doi.org/10.1007/BF02598290